How do we develop nanopharmaceuticals under open innovation?

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 4, 2011, Pages 371-375

  Eaton, Michael A W ^a  

^a European Technology Platform for Nanomedicine   (Germany)

Author keywords

Commercialization; Development; Nanomedicine; Social responsibility; Translation

Indexed keywords

COMMERCIALIZATION; DEVELOPMENT; DEVELOPMENT PLANS; NANOMEDICINES; NANOPHARMACEUTICALS; OPEN INNOVATION; PHARMACEUTICAL SECTOR; SOCIAL RESPONSIBILITIES;

MEDICAL NANOTECHNOLOGY;

CARBON NANOTUBE; DISULFIDE; POLYMER; SILICON DIOXIDE;

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; COMMERCIAL EVALUATION; COMPETITIVE EVALUATION; DIALYSIS MEMBRANE; DRUG ANALYSIS; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; ECONOMIC EVALUATION; EVALUATION; HUMAN; KIDNEY CLEARANCE; NANOMEDICINE; NANOPHARMACEUTICS; PATENT; PEER REVIEW; REGULATORY EVALUATION; REIMBURSEMENT; RESEARCH PRIORITY; RISK ASSESSMENT; SCALE UP; TECHNICAL EVALUATION;

NANOMEDICINE;

EID: 79960739168     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.05.015     Document Type: Article

References (13)

1. Eaton M. Nanomedicine: industry-wise research. Nat Mater 2007, 6:251-253.
2. Nanomedicine: The European Technology Platform Accessed July, 2011. http://www.etp-nanomedicine.eu/public.
3. Ackland G. Patent WO 2008/001053 A1 2008.
4. Ackland G, Gourine A. Patent WO 2008/001055 A1.
5. Parton T., King L., Parker G., Nesbitt A. The PEG moiety of certolizumab pegol is rapidly cleared from the blood of humans by the kidneys once it is cleaved from the Fab'. Inflamm Bowel Dis 2009, 15:S56.
6. Winzor D.J. Reappraisal of disparities between osmolality estimates by freezing point depression and vapor pressure deficit methods. Biophys Chem 2004, 107:317-323.
7. http://www.seroscience.com/. Accessed July, 2011.
8. Sauerborn M, Schellekens H Curr Opin Biotechnol 2009, 20:715-721.
9. Armstrong J.K., Hempel G., Koling S., Chan L.S., Fisher T., Meiselman H.J., et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110:103-111.
10. Junutula J.R., Raab H., Clark S., Bhakta S., Leipold D.D., Weir S., et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008, 26:925-932.
11. Khan M.N. Kinetics and mechanism of the alkaline hydrolysis of maleimide. J Pharm Sci 1984, 73:1767-1771.
12. Palframan R., Airey M., Moore A., Vugler A., Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Meth 2009, 348:36-41.
13. Asharani P.V., Wu Y.L., Gong Z., Valiyaveettil S. Toxicity of silver nanoparticles in zebrafish models. Nanotechnology 2008, 19:255102.